Frontotemporal dementia (FTD) is a heterogeneous clinical syndrome associated with frontotemporal lobar degeneration (FTLD) as a relatively consistent neuropathological hallmark feature. However, the discoveries in the past decade of many of the relevant pathological proteins aggregating in human FTD brains in addition to several new FTD causing gene mutations underlined that FTD is a diverse condition on the neuropathological and genetic basis. This resulted in a novel molecular classification of these conditions based on the predominant protein abnormality and allows most cases of FTD to be placed now into one of three broad molecular subgroups; FTLD with tau, TAR DNAbinding protein 43 or FET protein accumulation (FTLDtau, FTLD-TDP and FTLD-FET respectively). This review will provide an overview of the molecular neuropathology of non-tau FTLD, insights into disease mechanisms gained from the study of human post mortem tissue as well as discussion of current controversies in the field.
Introduction
Frontotemporal dementia (FTD) is a clinically, genetically and neuropathologically heterogeneous neurodegenerative syndrome. It accounts for 5-15% of all dementias and is the second commonest cause of dementias in the presenile age group (<65 years) after Alzheimer's disease (AD). The clinical presentation is characterized by progressive deterioration in behaviour, personality and/or language, with relative preservation of memory. Based on the predominant features, FTD typically comprises three clinical syndromes: behavioural variant of FTD (bvFTD) and two forms of primary progressive aphasia (PPA) which can be further subdivided into a nonfluent variant (nfvPPA) or a semantic variant of PPA (svPPA); however, these phenotypes often converge as the disease progresses. In addition, patients with FTD may also develop extrapyramidal movement abnormalities (i.e. parkinsonism, corticobasal syndrome) or motor neuron disease (MND) [1] .
Given the clinical heterogeneity, it is not surprising that the molecular basis of FTD is also heterogeneous. Neuropathologically, patients with FTD show a relatively selective frontal and temporal lobar degeneration (FTLD) and, like in most other neurodegenerative disorders, almost all cases of FTLD brains are characterized by the presence of protein deposits forming distinct inclusion bodies in cells of the central nervous system. Until 2006, only FTLD forms with aggregation of the hyperphosphorylated tau protein were well characterized, while the majority of FTD cases were associated with tau-negative, ubiquitin-positive inclusions with unknown protein identity, and therefore termed FTLD-U [2] . With the discovery of the TAR DNA-binding protein 43 (TDP-43) as disease protein in the vast majority of FTLD-U cases [3, 4] and the subsequent identification of aggregation of all members of the FET protein family [consisting of fused in sarcoma (FUS), Ewing's sarcoma protein (EWS) and TATA-binding protein associated factor 2N (TAF15)] in remaining FTLD-U cases [5, 6] , the enigma of the aggregating proteins in the vast majority of FTLD-U has been resolved. As a result, classification of FTLD into broad molecular categories on the basis of the molecular defect thought to be most characteristic and to most closely reflect the underlying pathogenic process and pathogenetic relevance has become a popular approach, allowing now to classify almost all FTD cases into three major molecular subgroups based on the disease signifying protein deposits: FTLD-tau, FTLD-TDP and FTLD-FET ( Figure 1 ) [7] .
Importantly, the dissection of the underlying molecular neuropathology of FTD was paralleled by major progress in our understanding of the genetic basis of FTD. FTD is highly heritable with a positive family history of dementia present in 25-50% of cases, mainly with an autosomal dominant pattern of inheritance. With the discovery of mutations in MAPT in 1998, only about 5-20% of familial FTD cases, associated with FTLD-tau, could be explained [8] . This changed dramatically with the identification of mutations in the progranulin (GRN) gene and the chromosome 9 open reading frame 72 (C9orf72) gene, both associated with FTLD-TDP, as other major causes of familial FTD allowing now to explain the majority of autosomal dominant FTD forms [9] [10] [11] [12] . Almost all cases of frontotemporal lobar degeneration (FTLD) are characterized by abnormal protein deposits and can be classified into specific molecular subgroups based on the deposited proteins. The most common subgroups are FTLD-TDP and FTLD-tau (accounting for approximately 50% and 40%, respectively) followed by FTLD-FET (accounting for approximately 5-10%) and FTLD-UPS (<1%). Within the FTLD-TDP subgroup, the subset of cases caused by chromosome 9 open reading frame 72 (C9orf72) mutations show dipeptide repeat protein (DPR) deposition in addition to TDP-43 pathology. Based on the morphology and regional distribution of inclusions, specific pathological subtypes of FTLD-tau, FTLD-TDP and FTLD-FET can be delineated. Genetic forms of FTLD-tau are associated with mutations in the MAPT gene; familial forms of FTLD-TDP are most often associated with defects in the genes GRN or C9orf72, while mutations in valosin-containing protein gene (VCP), TARDBP and TBK1 are only very rarely found in FTLD-TDP. All neuropathologically confirmed FTLD-FET cases have thus far not been associated with a known gene defect; however, mutations in the fused in sarcoma (FUS) gene are on occasion described in patients with clinical features of frontotemporal dementia (FTD). FTLD-UPS was introduced for very rare forms of FTLD associated with inclusions only labelling for markers of the ubiquitin/proteasome system (UPS). So far, all such cases are associated with mutations in CHMP2B. AGD, argyrophilic grain disease; aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions; BIBD, basophilic inclusion body disease; CBD, corticobasal degeneration; GGT, globular glial tauopathy; NIFID, neuronal intermediate filament inclusion body disease; PiD, Pick's disease; PSP, progressive supranuclear palsy.
Here, we review the current concept of the molecular neuropathology of non-tau FTLD subtypes with emphasis on insights from human post mortem studies on disease mechanisms. For information on the neuropathology and molecular mechanisms underlying FTLD-tau we would like to refer to previous review articles [13, 14] .
FTLD-TDP
Following an immunological approach, TDP-43 was identified in 2006 as the aggregating protein in the vast majority of previously labelled FTLD-U cases (now termed FTLD-TDP), and in most cases of amyotrophic lateral sclerosis (ALS) [3] . In most series, FTLD-TDP is the most common molecular subgroup underlying FTD accounting for about 50% of all FTLD cases including sporadic and familial forms. Degeneration consistently includes the frontal and temporal lobes while involvement of other cortical and subcortical structures such as the parietal cortex, basal ganglia, substantia nigra and motor neurons is common although more variable among cases. Hippocampal sclerosis with severe loss of neurons from CA1 and subiculum is present in more than 50% of cases. No inclusions are seen by conventional staining techniques such as H&E, silver impregnation methods or thioflavin S and immunohistochemical assessment is required for diagnosis.
The pathological hallmark lesions of FTLD-TDP are neuronal cytoplasmic inclusions (NCI), neuronal intranuclear inclusions (NII) and dystrophic neurites (DN) that are immunoreactive for TDP-43 (Figure 2 ), as well as ubiquitin and p62, but negative for other neurodegenerative disease-related proteins such as tau, a-synuclein, or FUS [7] . In addition, previously unrecognized ubiquitin-negative pathology is recognized by TDP-43 immunohistochemistry, including granular cytoplasmic immunoreactivity in neurons described as diffuse/granular inclusions ('pre-inclusions') [15] or 'dash-like' aggregates [16] , delicate wispy neuritic threads and dots in the CA1 region and affected cortices [17, 18] , and glial cytoplasmic inclusions (GCI) in oligodendrocytes [19] . Inclusions are typically most abundant in the frontotemporal neocortex and the dentate granule cells of the hippocampus; however, most cases also show significant TDP-43 pathology in many subcortical regions including the amygdala, striatum, thalamus, substantia nigra and inferior olives [20, 21] . Importantly, the amount and regional distribution of TDP-43 pathology in the CNS shows strong associations with the degree of neurodegeneration [21, 22] . Despite their common feature of TDP-43 accumulation, significant heterogeneity is observed within FTLD-TDP cases with respect to morphology, abundance/presence of distinct inclusion types and their laminar distribution with important clinico-pathological and genetic associations as discussed below.
TDP-43 inclusion body formation is associated with a dramatic reduction of the physiological nuclear staining of TDP-43 (Figure 2A) . Biochemically, pathological forms of TDP-43 show a number of abnormal post-translation modifications, including hyperphosphorylation, ubiquitination and N-terminal truncation ( Figure 2B ) [3, 4, 23, 24] . As a result, antibodies that specifically recognize pathological forms of TDP-43 (e.g. phosphorylated at site S409/410) have further facilitated the detection of TDP-43 pathology and are considered to be the most sensitive method for histological evaluation of TDP-43 pathology ( Figure 2C ) [18, 25] .
TDP-43 functions and pathomechanisms
TDP-43 is a highly conserved, ubiquitously expressed 414 amino acid DNA/RNA-binding protein with a tightly autoregulated expression level. It is mainly localized to the nucleus but has been shown to continuously shuttle between the nucleus and the cytoplasm. As an RNA-binding protein with two RNA binding motifs, TDP-43 is involved in multiple aspects of RNA metabolism in the nucleus and the cytoplasm, including transcription, splicing, mRNA transport and stabilization as well as stress granule formation [26] [27] [28] . Indeed, TDP-43 binds to >6000 RNA species in the central nervous system with an enrichment for long transcripts, and those related to neuronal development and synaptic functions [29, 30] . The C-terminal region of TDP-43 encodes for a glycine-rich low-complexity domain with similarities to yeast prion proteins, therefore also called 'prion-like' domain [31] . This region is considered to be the 'amyloidogenic' core of the protein, as it can mediate liquid-liquid phase transition and the formation of solid amyloid-like fibres in vitro upon nonphysiologically high protein concentrations. Thus, it is speculated that similar processes might be involved in vivo in the formation of messenger ribonucleoprotein particles (mRNPs), such as stress granules
or transport granules, and that physiological mRNP granule assembly mechanisms and dynamics may become altered in FTLD-TDP giving rise to solidified, dysfunctional mRNP granules and eventually TDP-43 aggregates [26] . This is supported by the colocalization of stress granule markers to a subset of TDP-43 inclusions enriched for full-length TDP-43 in human tissues [32] , although TDP-43 aggregates in human patients, in contrast to the in vitro formed fibres in phase transition studies, do not stain positive for amyloid dyes such as Thioflavin S and Congo red [33] .
Overall, the precise functions of TDP-43 in the brain, the molecular basis of cytoplasmic TDP-43 aggregation and especially the contributions of loss-of-function and gain-of-function mechanisms in disease pathogenesis and cell death of the various sporadic and genetic forms of FTLD-TDP still remain to be determined [28, 34] . However, given the intimate association between nuclear TDP-43 depletion and cytoplasmic accumulation of post-translationally modified TDP-43 species, it is most likely that complex disturbances of nuclear and cytoplasmic functions together with generation of toxic species may contribute to cell death. Briefly, in support of a nuclear loss-of-function mechanism, TDP-43 functions in the brain are essential during development and for neuronal survival in mouse models [35] [36] [37] [38] [39] and alternative splicing changes including enhanced TDP-43-associated cryptic exon splicing indicative of loss of nuclear TDP-43 functions have been reported in ALS/FTD post mortem tissues [40] [41] [42] . The cytoplasmic accumulation of TDP-43 might result in loss of cytoplasmic functions (e.g. axonal mRNA trafficking) or aggregating TDP-43 species may acquire novel toxic properties. The latter is supported by the finding that C-terminal fragments induce toxicity and cell death in yeast, cultured cells and transgenic mice [34] .
Pathological FTLD-TDP subtypes
Prior to the identification of TDP-43, heterogeneity of ubiquitin-immunoreactive pathology was noted among FTLD-U cases [43, 44] . Following the discovery of TDP-43, the same pathological criteria have been used to classify FTLD cases based on differences in the morphology and cortical laminar distribution of the inclusions and four pathological subtypes of FTLD-TDP are recognized, each with relatively specific clinical and genetic correlations (Table 1) [45]. However, the fact that immunohistochemistry for ubiquitin and TDP-43 each recognizes slightly different pathological changes in FTLD-TDP implied that the original FTLD-U subtype criteria may not be directly applicable for use with TDP-43 immunohistochemistry and therefore the criteria for FTLD-TDP subtypes have been recently formally re-evaluated by comparing ubiquitin, TDP-43 and phospho-TDP immunohistochemistry and refined criteria have been proposed (Table 2 ) [18] .
Type A cases are characterized by TDP-43-positive abundant short thick DN and compact oval or crescentic NCI, predominantly in layer II of the neocortex (Figure 2D ) and lentiform NII are a consistent finding in affected cortical regions ( Figure 2H ). Moderate numbers of granular NCI are present in the dentate granule cells of the hippocampus. TDP-43-positive GCI are present in the cerebral white matter ( Figure 2K ) and in affected subcortical regions which include the striatum (Figure 2I ), thalamus and substantia nigra. The clinical presentation is usually either bvFTD or nfvPPA.
Type B cases show moderate or numerous TDP-43-positive NCI in both superficial and deep cortical layers, with diffuse granular cytoplasmic NCI being more abundant than compact NCI ( Figure 2E ). NII are absent and short thick DN are typically sparse; however, delicate wispy threads and dot-like profiles may be abundant ( Figure 2E ). TDP-43-positive NCI (diffuse granular and compact) are often present in lower motor neurons (LMNs; Figure 2J ), even in the absence of clinical features of ALS.
Type C cases have abundant long and tortuous TDP-43-positive DN which are usually more abundant in the upper cortical layers, ( Figure 2F ). NCI are present in variable numbers in the hippocampus, usually with a compact, round morphology, while they are rare in the neocortex. GCI are uncommon and NII are usually absent. This is the most common pathological subtype found in FTD cases presenting with svPPA.
Type D corresponds to a unique pattern of FTLD-TDP pathology, so far only seen in cases with mutations in the valosin-containing protein gene (VCP). It is characterized by the abundance of TDP-43-positive lentiform NII and short DN in the neocortex with only rare NCI ( Figure 2G ) [45, 46] . Notably, the hippocampus is spared while other regions such as the basal ganglia, thalamus and midbrain show variable TDP-43 pathology.
Although most FTLD-TDP cases can easily be assigned to one of the common subtypes (A-D), several studies have found that a minority of cases are difficult to classify; either because the pattern of pathology is felt not to fit with any of the existing subtypes [47] [48] [49] or because it shows overlapping features of more than one subtype [48, 50, 51] . A recent study that evaluated the TDP-43 pathology in a large series of cases using an unbiased semiquantitative approach found that 19% had the positive pathological features of both type A and type B [18] . Possible interpretations offered include that these cases represent a unique pathological subtype (supported by the relatively specific clinicogenetic correlation with the majority of cases carrying C9orf72 mutations and all presenting with FTD + ALS), the co-occurrence of two existing subtypes (difficult to reconcile with the current consensus diagnostic recommendations which includes both inclusion and exclusion criteria for each subtype) or evidence that the existing subtypes represent an overlapping spectrum rather than discrete entities (as has been suggested by unbiased principal components analysis [50], but not supported by the consistent strong clinical and genetic correlations). Another recent report by Lee et al. described a small series of cases with rapidly progressive FTD that the authors felt were associated with a novel pattern of FTLD-TDP, characterized by a predominance of granulofilamentous NCI and abundant fine grain-like deposits in all neocortical layers, which they referred to as 'type E' [49] . Although the findings and interpretations of both of these studies require validation by other groups, they do illustrate the need for ongoing reappraisal and possible updating of the FTLD-TDP classification system as well as multicentre, multi-investigator studies to validate the diagnostic accuracy of proposed criteria.
Familial forms of FTLD-TDP
GRN mutations Progranulin (PGRN) is a multifunctional secreted growth factor that regulates cell growth and survival, wound repair and inflammation [52] . Mutations in the progranulin gene (GRN) are the cause of 5-20% of familial FTD [9, 10] . Most pathogenic GRN mutations result in null alleles and all appear to cause disease by reducing the amount of functional PGRN (haploinsufficiency). The clinical presentation is either bvFTD or nfvPPA, and some degree of parkinsonism is common but ALS is exceptionally rare [1, 52] . Notably, despite the uniform molecular consequences of GRN mutations, the clinical symptoms can vary significantly even among affected individuals within the same family, implicating additional (genetic/environmental) factors as disease modifiers. The associated pathology is consistently FTLD-TDP type A with moderate numbers of lentiform NII ( Figure 2D,H) [18, 53, 54] . The striatum tends to be the most severely affected subcortical region and there is often hippocampal sclerosis associated with numerous delicate DN.
The exact mechanism by which reduced levels of PGRN leads to neurodegeneration and TDP-43 aggregation is unknown; however, there is growing evidence for a role of lysosomal dysfunction [55] . Homozygous mutations in GRN cause a form of lysosomal storage disease (neuronal ceroid lipofuscinosis) [56] and FTD patients with PGRN haploinsufficiency show some histological and biochemical similarities with those cases [57, 58] . Moreover, variations in the gene that encodes the lysosomal protein TMEM106B influences the risk of GRN mutation carriers in developing FTD [59] [60] [61] .
C9orf72 mutations Abnormal expansion of a GGGGCC hexanucleotide repeat in a noncoding region of the C9orf72 gene is the most common genetic cause of familial and sporadic forms of both FTD and ALS and the basis of most families in which both conditions occur [11, 12] . The most commonly associated FTD phenotype is bvFTD; however, a wide range of neurological and psychiatric features are recognized, including nfvPPA, memory deficits, extrapyramidal movement disorders and psychosis with significant clinical heterogeneity among affected members of a family with the C9orf72 mutation [1, 62] .
For the C9orf72 repeat expansion mutation, three pathogenic mechanisms are proposed: (i) toxicity of proteins generated by unconventional repeat-associated non-ATG (RAN) translation of transcripts, (ii) toxic RNA gain of function by sequestration of RNA-binding proteins to transcripts with expanded repeats and (iii) haploinsufficiency [63] .
As a result, the neuropathology associated with C9orf72 mutation is complex, consisting of variable TDP-43 pathology as well as pathological features directly linked to the expanded repeats. The significance of the various described pathological changes in disease pathogenesis as well as the association between C9orf72 mutations and TDP-43 aggregation are currently not resolved; however, none of the mechanisms seem to be sufficient by its own, suggesting a more complex interplay between the different pathologies.
TDP-43 pathology in C9orf72 mutation cases is some combination of FTLD-TDP and typical ALS with TDP-43 inclusions in motor neurons ( Figure 2J ) [22, 62, 64] . The neocortical TDP-43 pathology is most often type B ( Figure 2E) ; however, some older patients, usually with a pure dementia syndrome, show features more consistent with FTLD-TDP type A or a combination of types A and B [18, 22, 62, 65] . The presence of this dual pattern of FTLD-TDP has been strongly associated with advanced age and longer disease duration [62] . There is a strong association of TDP-43 burden and regional distribution with clinical phenotypes and degeneration suggesting that alterations due to the C9orf72 mutation resulting in TDP-43 accumulation and dysmetabolism as secondary downstream effects likely play a central role in C9orf72 disease pathogenesis [22, 66] .
A pathognomonic feature of FTLD-TDP due to a C9orf72 mutation is the additional presence of TDP-43-negative, but ubiquitin-and p62-positive inclusions [11] . This TDP-43-negative pathology is the result of unconventional repeat associated non-ATG initiated translation of the massively expanded hexanucleotide repeat [67] [68] [69] [70] [71] . Bidirectional translation in the various reading frames generates five different dipeptide repeat (DPR) proteins; glycine-alanine (sense strand), glycinearginine (sense strand), glycine-proline (GP, generated in both directions), proline-alanine (antisense strand) and proline-arginine (antisense strand). Antibodies against these DPR proteins specifically label the TDP-43-negative inclusions in all C9orf72 mutation cases, with those that recognize the products of the sense transcripts consistently labelling more pathology than those from antisense transcripts [66, [72] [73] [74] . DPR pathology includes coarse granular NCI, short DN and small dot-like NII with a highly uniform anatomical distribution among cases independent of their clinical phenotypes [22, 66, 72, 74, 75] . They are abundant in all regions of the cerebral neocortex, limbic cortex, hippocampus and cerebellar cortex ( Figure 2L-N) , more variable in the basal ganglia, thalamus and upper brainstem and rare or absent in the lower brainstem and spinal cord. The demonstration of toxicity of the DPR proteins in a variety of cell culture models, Drosophila and mouse models support their potential pathogenic role [63, 76, 77] . Although the results of these experimental studies have been inconsistent as to which specific DPR species are toxic and what the mechanism of injury is, there is growing evidence that DPR accumulation could lead to nucleocytoplasmic transport defects [76] [77] [78] . However, the consistent lack of any associations between the amount and/or anatomical distribution of DPR protein pathology with degeneration or clinical features in clinico-pathological correlation studies of patients with the C9orf72 mutation [22, 66, [72] [73] [74] [75] , suggests that disease is not simply and exclusively due to a direct toxic effect of DPR aggregates on neurons.
Another characteristic finding in C9orf72 mutation cases is the presence of intracellular RNA aggregates (RNA foci) composed of the mutant sense and antisense transcripts that can be recognized by in situ hybridization ( Figure 2O ). Up to 50% of neuronal nuclei contain RNA foci while they are less frequently seen in the neuronal cytoplasm and in glial cells [11, 68, 79, 80] . These foci show no specific colocalization or association with either DPR or TDP-43-positive inclusions [79] . Notably, besides a moderate association between the percentage of cells with antisense RNA foci in the frontal cortex and a delayed age at onset, no other associations with clinico-pathological features were seen in a detailed large-scale study, indicating that RNA foci pathology alone is not sufficient to trigger neurodegeneration [80] . The formation of RNA foci might result in a toxic-gain-of-function by sequestering and inactivating crucial RNA binding proteins. While a number of studies using human tissue, experimental animals and various cell models have identified a long list of potential interacting proteins; there is little agreement among the results and no consensus as to the most important candidates [63, 81, 82] .
Finally, reduced transcription of the mutant allele is predicted to result in haploinsufficiency of the long protein isoform, which has been demonstrated at the transcript [11, 83, 84] and protein levels in tissues of C9orf72 mutation carriers [85] [86] [87] . Although incomplete knowledge of the normal protein function particularly in the CNS and the fact that C9orf72 knock-out mice do not develop a neurodegenerative phenotype makes the impact of C9orf72 insufficiency unpredictable, recent studies have shown that C9orf72 is part of a protein complex containing Smith-Magenis syndrome chromosomal region candidate gene 8 (SMCR8) and WD repeat-containing protein 41 (WDR41). This complex may act as guanine nucleotide exchange factor for specific Rab GTPases, such as RAB8A and RAB39B involved in autophagy thereby modulating different steps of the autophagy and endolysosomal pathways [88] and there is some evidence that impaired formation and trafficking of endosomal and lysosomal vesicles may contribute to neurodegeneration in iPSC-derived motor neurons [89] .
VCP mutations Mutations in VCP are the cause of a rare autosomal dominant syndrome characterized by variable penetrance of inclusion body myopathy, Paget's disease of the bone and FTD [90] . VCP is a member of the AAA-ATPase gene superfamily, and functions as a molecular chaperone in a wide range of distinct cellular activities, most of which are regulated by the UPS. Consequences of VCP mutations include disturbed UPS degradation and autophagy [91] . VCP mutation cases with FTD present with the unique FTLD-TDP type D with numerous NII and DN in the neocortex ( Figure 2G ) [45, 46] . TARDBP mutations Mutations in the TARDBP gene encoding TDP-43 are most often associated with clinically pure ALS [92] [93] [94] , but can also result in ALS combined with FTD [95] or even pure FTD [96] [97] [98] . Descriptions of the neuropathology in cases with FTD are few and the pathogenicity of the reported mutations remains unclear due to current lack of evidence of segregation with the disease. Although TDP-43 pathology seems to be a consistent feature in these cases, the pattern of FTLD-TDP is not consistent, often difficult to classify and may be combined with a more complex proteinopathy [99] [100] [101] [102] . Some of the clinical and pathological variation associated with TARDBP mutations may reflect recent findings that different mutations may have different pathomechanisms, including both loss of function and gain of RNA splicing activity [103, 104] .
Mutations in other genes associated with FTLD-TDP Mutations in many other genes, often initially discovered as uncommon causes of ALS, have subsequently been identified in patients with FTD AE ALS. Although reports on the associated neuropathology are still rare, TDP-43 pathology has been described in cases with mutations in genes encoding TANK-binding kinase 1 (TBK1) [105] [106] [107] [108] [109] , sequestosome 1 [110, 111] , ubiquilin 2 [112, 113] , optineurin [105] and dynactin [114] . Current information is insufficient to know if any of these mutations is associated with a unique pathological signature; however, in the case of TBK1 mutations, the associated pattern of TDP-43 pathology is reported to be inconsistent (FTLD-TDP type A or B) with unusual presence of numerous TDP-43-positive neuritic structures at the cerebral cortex/ subcortical white matter junction reported in one case [109] .
Evidence for spreading of TDP-43 pathology and FTLD-TDP stages
There is increasing experimental evidence for prion-like propagation and progression as a common pathomechanism in many neurodegenerative diseases [115] . The general concept involves the cell-to-cell transfer of minute amounts of a misfolded pathological protein which is sufficient to initiate template-directed misfolding of the respective native protein in the recipient cell, resulting in the spreading of pathology from one brain region to another. In vivo support for this concept comes from cross-sectional studies of human post mortem tissue that show a consistent hierarchical anatomical distribution of certain pathologies, such as the neurofibrillary changes in AD (i.e. Braak stages) suggestive of a transsynaptically spreading of tau pathology between interconnected neuroanatomical regions [116] . Although some in vitro and cell culture experiments suggest that TDP-43 might have similar prion-like spreading and propagation properties as illustrated by aggregation of TDP-43 in vitro triggered by recombinant TDP-43 fibrils and insoluble TDP-43 isolated from FTD/ALS brains (reviewed in [117] ), the in vivo evidence is still not well established.
As an attempt to establish stages of disease progression, Brettschneider et al. evaluated the anatomical distribution of TDP-43 pathology in post mortem material from cases with clinical ALS [118] and FTLD-TDP with bvFTD [119] and identified progressive involvement of different specific clusters of anatomical regions. Cases with ALS all showed pathology in the motor cortex, brainstem and spinal cord motor nuclei (stage 1), with progressively smaller sets of cases also showing involvement of areas identified as stage 2 (prefrontal cortex, reticular formation, precerebellar nuclei and red nucleus), stage 3 (prefrontal, post-central cortex and striatum) and stage 4 (anteromedial temporal lobe and hippocampus); respectively. Although the authors proposed that these findings were consistent with the propagation of TDP-43 pathology along specific axonal pathways [120] , the study did not find any correlation between the pathological stages and the duration or severity of ALS, suggesting that the 'stages' may only reflect different distributions of end-stage TDP-43 pathology. Similarly, cases of FTLD-TDP with bvFTD were found to demonstrate four patterns with progressive involvement of (i) orbital gyri, gyrus rectus and amygdala, (ii) middle frontal, anterior cingulate, anteromedial temporal lobe, superior and medial temporal gyri, striatum, red nucleus, thalamus and precerebellar nuclei, (iii) motor cortex, bulbar somatomotor neurons and spinal cord anterior horn, and (iv) visual cortex. However, there was again no association with disease duration [119] . It is also uncertain how much the various patterns identified in these two studies were simply a reflection of selection bias, since the study of ALS patients included a minority that also had clinical FTD [118] and one-third of the cases in the study of bvFTD also had clinical features of ALS [119] . Although the wide variation in clinical presentation and disease course associated with TDP-43 pathology does not exclude the possibility of prion-like propagation, it strongly suggests that, if spreading occurs, it does not start at a single site and does not follow a consistent hierarchical pattern in all FTLD-TDP cases.
TDP-43 pathology in other neurodegenerative diseases
Concomitant TDP-43 pathology can be seen in a significant number of AD cases with reported frequencies ranging from 20-60%, as well as in a smaller proportion of cases with other neurodegenerative diseases such as Lewy body diseases or corticobasal degeneration [121] [122] [123] [124] [125] . TDP-43 pathology is also strongly associated with hippocampal sclerosis which often occurs in the context of other neurodegenerative diseases (most frequently AD and FTLD) but also in elderly individuals (>85 years) without other significant comorbid pathology, referred to as hippocampal sclerosis dementia or hippocampal sclerosis of ageing [121, 126] .
Unlike in FTLD-TDP, TDP-43 pathology in AD and other conditions is most often restricted to the mesial temporal lobe and other limbic regions. However, there are a few examples showing extensive neocortical TDP-43 pathology more reminiscent of FTLD-TDP [122, 124, 125] . Whether these cases represent the coincidental presence of two independent diseases, that is, AD and FTLD-TDP (rather than secondary TDP-43 pathology) is currently not fully resolved; however, differences in the topographic distribution of TDP-43 pathology in AD cases vs. FTLD-TDP and the absence of clinical evidence of FTD or atypical clinical AD features in these cases argues against it [124] .
FTLD-FET
Following the identification of mutations in the FUS gene in autosomal dominant forms of ALS (ALS-FUS) [127, 128] , prompted researchers to investigate for a potential role of FUS in FTLD and indeed accumulation of FUS was found in the remaining FTLD-U cases not explained by TDP-43 [5, 129, 130] . However, subsequent analysis of those cases revealed notable differences to ALS-FUS. None of the FTLD cases with FUS pathology has yet been associated with a FUS gene mutation. Moreover, while inclusions in ALS-FUS cases only contain FUS protein, FUS-positive inclusions in FTLD cases show co-aggregation of all other FET protein members, TAF15 and EWS, as well as transportin 1 (the protein responsible for nuclear import of FET proteins) as highly consistent feature, implying a more complex dysregulation of all FET proteins ( Figure 3A ) [6, 131, 132] . As a result, these cases can be grouped together under the umbrella term FTLD-FET which accounts for 5-10% of all FTLD cases. The pathology of FTLD-FET includes NCI, NII, GCIs with distinct morphology and distribution patterns allowing to separate three distinct clinico-pathological entities as described below (Table 1) . Inclusion body formation is usually associated with reduced nuclear staining of FET proteins, although not as pronounced as seen for TDP-43 in FTLD-TDP. Biochemical alterations of FET proteins in disease state include changes in solubility [5, 6] as well as an altered arginine methylation status of the Cterminus, with FUS aggregates in FTLD-FET being unand monomethylated ( Figure 3B ), whereas it is dimethylated in healthy cells and ALS-FUS [133, 134] .
FET functions and pathomechanisms
FUS, EWS and TAF15 define a family of proteins known as FET protein family. These proteins are highly conserved, ubiquitously expressed, predominantly nuclear, multifunctional DNA/RNA-binding proteins initially discovered as components of fusion oncogenes that cause specific types of human cancer [135] . FET proteins are shuttling proteins and their nuclear import is mediated by a nonclassical nuclear localization signal, called PY-NLS, recognized by the nuclear import protein transportin 1 [136, 137] . Their functions include DNA repair, transcriptional regulation, pre-mRNA splicing, and other elements of mRNA processing and metabolism. FUS and TAF15 show a high percentage of overlapping RNA targets with enrichment of transcripts involved in synaptic transmission [138] [139] [140] . The normal physiological roles of each FET protein and their functional overlap in the brain is not completely understood, but studies suggest slightly divergent functions such as minor impact of TAF15 on alternative splicing compared to FUS [140] . Like TDP-43, all three FET proteins belong to the group of proteins with low complexity 'prion-like' domains driving liquid-liquid phase transition and aggregation in vitro therefore arguing for altered mRNP granule assembly also in FTLD-FET pathogenesis [26, 31] . Notably, arginine methylation of the C-terminus of FUS has been recently shown to suppress phase separation, implying that the observed loss of methylated FUS (and potentially TAF15 and EWS) in FTLD-FET might directly contribute to aggregation formation [141, 142] . Dissecting the molecular mechanism causing FET protein hypomethylation as well as identification of other potentially relevant alterations of post-translational modifications in FTLD-FET will be important next steps.
Pathological FTLD-FET subtypes
Atypical FTLD-U Cases referred to as 'atypical' FTLD-U (aFTLD-U) were originally recognized because the unique ubiquitin-positive, tau/TDP-negative pathology is associated with a highly consistent and unusual clinical presentation [143] [144] [145] . The phenotype tends to be sporadic, early-onset bvFTD (often <40 years) with severe, rapidly progressive psycho-behavioural changes, in the absence of significant language or motor features. In addition to frontotemporal atrophy, severe degeneration of the head of the caudate nucleus and hippocampal sclerosis is a highly consistent feature. FET-positive small, compact, round or oval NCI are most abundant in the frontal and temporal neocortex, hippocampus and striatum ( Figure 3C ,D) [5, 146] . NII with the unique morphology of single elongated straight, curved bar or twisted (vermiform) filaments are easily recognized in the dentate granule cells but also widespread in cortical pyramidal neurons and are perhaps the most intriguing and diagnostic lesion in aFTLD-U ( Figure 3E ). Cases of aFTLD-U tend to have more uniform NCI inclusion morphology and less pathology in subcortical regions than other FTLD-FET subtypes [146, 147] . Like in the other FTLD-FET subtypes, GCI may be present in the white matter of affected regions ( Figure 3K ).
Neuronal intermediate filament inclusion disease
Neuronal intermediate filament inclusion disease (NIFID) is a rare, clinically heterogenous neurodegenerative disorder typically presenting with sporadic early-onset FTD, MND and/or extrapyramidal motor symptoms. It was first recognized as a unique entity based on the neuropathological finding of NCIs that are immunoreactive for all class IV neuronal intermediate filaments (IF, neurofilament subunits and a-internexin) [148] . However, only a small number of NCIs are IFpositive, and much more abundant and anatomically widespread NCI pathology is labelled with antibodies against FET proteins. The morphology of FET-positive NCIs is very heterogenous ranging from round Pick body-like, crescentic, annular, tangle-like to coarse granular aggregates, involving the cerebral cortex, hippocampus, basal ganglia, thalamus, cerebellar dentate, numerous brainstem nuclei and usually the spinal cord LMN ( Figure 3F ,G,J). Moreover, FET immunohistochemistry reveals additional types of inclusions including filamentous/vermiform NII that are usually present in the hippocampus ( Figure 3E ) and GCIs ( Figure 3K ) in affected brain regions [6, 129, 146] .
The only type of NCI which are better labelled by IF immunohistochemistry are hyaline conglomerate inclusions [129] . Importantly however, IF-positive inclusions are always associated with FET accumulation in the same cell, while many more cells contain only FETpositive inclusions, suggesting that FET accumulation occurs earlier and is more central to NIFID pathogenesis; whereas, the accumulation of IF is more likely a secondary phenomenon [6, 129, 146] .
Basophilic inclusion body disease Basophilic inclusion body disease (BIBD) is an uncommon disease defined by the presence of round, well demarcated NCI that are basophilic on H&E stain (basophilic inclusion, BI). BI may be weakly argyrophilic and their basophilia has been attributed to their RNA content. The reported clinical presentation associated with BIBD pathology is very heterogeneous including FTD, juvenile or adultonset ALS, combined FTD/ALS, parkinsonism, chorea, dysarthria and gaze palsy [130, 149] . BIs strongly label for FUS and other FET proteins, but most importantly FET immunohistochemistry reveals much more and widespread NCI pathology with a wide spectrum of morphologies present in many cortical and subcortical regions (e. g. thalamus, basal ganglia, brainstem), and LMNs ( Figure 3H-J) [130, 146] and GCIs ( Figure 3K ) are a consistent finding. The FET-positive pathology overlaps with those seen in NIFID, although the amount of pathology in the hippocampus and striatum is more variable in BIBD. Moreover, the characteristic FET-positive NII seen in aFTLD-U and NIFID are consistently absent.
Genes and risk factors in FTLD-FET
The vast majority of cases with autopsy proven FTLD-FET are sporadic [145] and the role of FET gene mutations in causing FTD is still uncertain. Although FUS mutations have been reported in a small number of patients with clinical features of FTD (AEALS) [150] [151] [152] [153] , only one has undergone autopsy examination and this did not include immunohistochemistry for FUS and other FET proteins [154] . Genetic variants of TAF15 and EWS have been reported in a small number of ALS patients [155, 156] , however, the associated pathology in these cases is unknown. More recently the first neuropathological report of a FTD/ALS case with a novel TAF15 mutation (p.G462S) has been described, which surprisingly revealed FTLD-TDP subtype B pathology with absence of any FET pathology [111] . While a potential association between TAF15 mutations and TDP-43 pathology might be intriguing, it must be cautiously noted that no segregation analysis of the mutation could be performed within the family to substantiate its pathogenicity.
Despite the altered arginine methylation status of FET proteins in FTLD-FET [133, 134] , no mutations or altered expression of the relevant N-arginine methyltransferases has been identified [157] .
FTLD-UPS
?A3B2 twb=.26w?>With the identification of TDP-43 and FET as disease proteins in FTLD, the vast majority of tau-negative forms of FTLD can now be classified as either FTLD-TDP or FTLD-FET. There are very few cases left in which inclusions are present that only label for markers of the UPS and those cases are now referred to as FTLD-UPS. The most important example is familial FTD linked to chromosome 3, caused by truncation mutations in CHMP2B first identified in a large Danish pedigree [158] . Subsequently, a distinct C-terminal truncation mutation was found in a Belgian FTD cohort [159] . CHMP2B encodes for a protein belonging to the chromatin-modifying protein/charged multivesicular body protein family involved in recycling or degradation of cell surface receptors [160] . The neuropathology of the Danish family includes ubiquitin and p62-positive, but tau, TDP-43 and FUS-negative, granular NCI, predominantly in the dentate granule cells of the hippocampus [161, 162] . The presence of enlarged mannose-6 phosphate receptor-positive vacuoles in cortical regions is suggestive of altered endosome lysosome fusion and autophagic mechanism impairment [163] ; however, whether the UPS pathology in CHMP2B mutation cases represents the accumulation of some yet-to-be-identified disease-specific protein, or a more general defect in endosomal trafficking and lysosomal protein degradation remains to be clarified. In addition to the described truncation mutations associated with FTD-3, a small number of missense mutations have been described in patients presenting with FTD/ALS. However, pathogenicity of the missense mutations remains unclear so far [160] , due to current lack of demonstration of segregation with disease in familial cases and pathogenic consequences of missense mutations. Moreover, the fact that four ALS cases with CHMP2B missense mutations have been described to show TDP-43 pathology, while FTD-3 is devoid of TDP-43 pathology, are suggestive of different effects and disease mechanisms between CHMP2B missense and truncation mutations [160] .
Other neurodegenerative diseases associated with FTD
There are a number of other very rare genetic neurodegenerative conditions that can present with clinical FTD. Hereditary diffuse leukoencephalopathy with spheroids, pigmented orthochromatic leukodystrophy, and Nasu-Hakola disease, which are caused by mutations in genes related to macrophage/microglial activity [colony stimulating factor 1 receptor (CSF1R), triggering receptor expressed on myeloid cells 2 (TREM2) and TYRO protein tyrosine kinase binding protein (DAP12), respectively] can present with variable clinical features including personality and behavioural changes, dementia, depression, parkinsonism and seizures [164] [165] [166] . Neuropathologically, they share the features of myelin loss, axonal spheroids and pigment accumulation in macrophages and glia, preferentially affecting the anterior cerebral white matter [167, 168] . No protein inclusions have been reported in these conditions so far, in line with the idea, that these conditions reflect primary microglial disorders. Notably, while homozygous TREM2 mutations are associated with Nasu-Hakola disease, a number of rare heterozygous TREM2 mutations are considered risk variants associated with AD and FTD [169, 170] . These data are in good agreement with the increasing evidence for an important role for microglial dysfunction in neurodegenerative diseases including FTD; however, further studies are needed to dissect the possible role of TREM2 mutations in FTLD disease pathogenesis and how the degree of TREM2 protein defect of distinct mutations may contribute to the different clinical and neuropathological phenotypes.
In addition, a mutation in the gene encoding the protein kinase A type I-beta regulatory subunit (PRKAR1B) has been identified in a large family in which multiple members presented with an FTD-like syndrome and parkinsonism [171] . The associated neuropathology shares some features of NIFID with anatomically widespread NCI immunoreactive for all class IV neuronal IF. However, in contrast to NIFID, the inclusions are negative for FUS and positive for PRKAR1B. Subsequently, three other NIFID-like cases with FUS-negative inclusions have been reported; however, they lacked PRKAR1B mutations suggesting that mutations in PRKAR1B account for only a portion of these rare NIFID-like cases [172] .
Finally, other causes of dementia may occasionally fulfil clinical diagnostic criteria for FTD. Clinico-pathological studies revealed that approximately 10-20% of clinical FTD cases show other neurodegenerative pathologies [173, 174] , with AD being the most frequent other diagnosis. Although some studies have found a correlation between the regional severity of AD pathology in these frontal variants of AD, this has not been consistent [175, 176] . Other diseases that can mimic FTD phenotypes include dementia with Lewy bodies, cerebrovascular disease and atypical presentations of prion diseases, such as the relatively new entity of variable protease-sensitive prionopathy [173, 177, 178] .
While in the past FTLD cases with absence of inclusions bodies were considered as frequent subtype of FTLD and referred to as dementia lacking distinctive histopathology [179] , the vast majority of such cases can now be assigned to FTLD-TDP or FTLD-FET due to improved sensitivity of immunohistochemical analysis to detect pathological inclusions. However, exceptional cases with clinical features of FTD and a FTLD in which all routine and immunohistochemical stains fail to reveal the presence of any pathological inclusions might exist for which the designation FTLD-ni (for 'no inclusions') is the recommended term [7] .
Conclusion
There has been remarkable progress in our understanding of the molecular basis of FTLD including the discovery of most of the common FTD-causing genes and the identification of the major pathological proteins. While further studies of human FTD material and experimental models are needed to clarify the specific pathogenic mechanisms, current insights highlight the important contribution of lysosomal dysfunction and altered RNA metabolism as key events in FTLD. Importantly, despite the increasing complexity of FTLD on the molecular basis, there are striking patterns with strong clinico-pathological and geneticopathological correlations emerging, which are expected to be keys for further dissecting the specific pathogenic mechanisms underlying the distinct molecular FTLD subtypes and towards future personalized medicine and targeted therapies.
